These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21279986)

  • 1. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
    Teitelbaum SL; Seton MP; Saag KG
    Arthritis Rheum; 2011 Feb; 63(2):325-8. PubMed ID: 21279986
    [No Abstract]   [Full Text] [Related]  

  • 2. Shoring Up Osteoporosis Management: A Fresh Start?
    Furr N; Ulmer A; Cardon B
    J Am Board Fam Med; 2024; 37(3):490-493. PubMed ID: 39142871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.
    Beukelman T; Saag KG; Curtis JR; Kilgore ML; Pisu M
    Osteoporos Int; 2010 Sep; 21(9):1573-84. PubMed ID: 19937227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconsidering the Benefits of Osteoporosis Treatment: The Case of Bisphosphonates.
    Goodman CW
    Am J Med; 2024 Jun; 137(6):476-478. PubMed ID: 38401675
    [No Abstract]   [Full Text] [Related]  

  • 5. A reappraisal of generic bisphosphonates in osteoporosis.
    Kanis JA; Reginster JY; Kaufman JM; Ringe JD; Adachi JD; Hiligsmann M; Rizzoli R; Cooper C
    Osteoporos Int; 2012 Jan; 23(1):213-21. PubMed ID: 21953472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a computerized clinical decision support system for prevention of glucocorticoid-induced osteoporosis.
    Morikawa T; Sakuma M; Nakamura T; Sonoyama T; Matsumoto C; Takeuchi J; Ohta Y; Kosaka S; Morimoto T
    Sci Rep; 2022 Sep; 12(1):14967. PubMed ID: 36056121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for osteoporosis: from bench to clinic.
    Bellido T
    J Clin Invest; 2024 Mar; 134(6):. PubMed ID: 38488010
    [No Abstract]   [Full Text] [Related]  

  • 8. A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England.
    Chalitsios CV; Shaw DE; McKeever TM
    NPJ Prim Care Respir Med; 2020 Feb; 30(1):5. PubMed ID: 32054843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases.
    Buttgereit F; Palmowski A; Bond M; Adami G; Dejaco C
    Nat Rev Rheumatol; 2024 Jul; 20(7):417-431. PubMed ID: 38831028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence in the pharmacological treatment of osteoporosis.
    Carbonell-Abella C; Torguet Carbonell J; Martínez Martí M
    Med Clin (Barc); 2024 Jun; 162(11):e59-e63. PubMed ID: 38614904
    [No Abstract]   [Full Text] [Related]  

  • 11. GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE.
    Saag KG
    Trans Am Clin Climatol Assoc; 2023; 133():69-80. PubMed ID: 37701582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.
    Taylor AD; Saag KG
    Core Evid; 2019; 14():41-50. PubMed ID: 31692480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage.
    Kim Y; Kim J; Lee H; Shin WR; Lee S; Lee J; Park JI; Jhun BH; Kim YH; Yi SJ; Kim K
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31430857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.
    Raterman HG; Bultink IEM; Lems WF
    Drugs; 2019 Jul; 79(10):1065-1087. PubMed ID: 31201710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
    Zhao J; Li Y; Zhang H; Shi D; Li Q; Meng Y; Zuo L
    J Bone Miner Metab; 2019 Sep; 37(5):805-814. PubMed ID: 30706148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
    Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
    Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy.
    Lems WF; Baak MM; van Tuyl LH; Lodder MC; Dijkmans BA; Boers M
    RMD Open; 2016; 2(2):e000313. PubMed ID: 27651928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
    Lems WF; Saag K
    Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.